Cue Health

Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nobilis Health Corp. engages in the operation and development of outpatient surgery centers. The firm owns and manages ambulatory and acute care facilities to deliver innovative surgical services. It operates through Medical Services and Marketing Services segment. The Medical Services segment provides the operation of hospitals, outpatient facilities, and other various related health care services. The Marketing Services segment provides marketing services, patient education services, and patient care coordination management services. The company was founded on March 16, 2007 and is headquartered in Houston, TX.

Cue Health Inc. (HLTH) CEO Ayub Khattak Q4 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, (“Cue") today reported financial results for fourth quarter and full year 2021. Key Highlights Reported total revenue of $192.5 million for the fourth quarter of 2021, compared to $13.3M in the fourth quarter of 2020 Full year revenue of $618.1 million in 2021, compared to $23.0 million in 2020 Diluted EPS of $0.22 for the fourth quarter of 2021, compared to a loss of $1.16 in the fourth quarter of 2020

Cue Health Reports Strong Fourth Quarter and Full Year 2021 Financial Results

Cue® helps the nation's premiere high school basketball showcase return to in-person action SAN DIEGO , March 28, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), the healthcare technology company behind the country's most accurate at-home COVID-19 test*, today announced that its COVID-19 test will be the preferred on-site test to help support the health and safety of the student-athletes and staff at the 2022 McDonald's All American Games . The Games will celebrate 45 years of showcasing basketball's brightest young stars by returning to in-person action in Chicago tomorrow, March 29.

Cue Health Serves as Preferred Testing Provider for the 2022 McDonald's All American Games

Albertsons Companies

Convenient In-Pharmacy Testing Now Available in 900 Stores Nationwide SAN DIEGO and BOISE, Idaho, March 22, 2022 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, and Albertsons Companies (NYSE: ACI) today announced a first-of-its-kind partnership that offers customers access to Cue's highly accurate, convenient, and fast molecular COVID-19 tests at participating Albertsons Cos. pharmacies across the country.

Cue Health and Albertsons Companies Partner to Provide Customers with Fast and Highly Accurate COVID-19 Testing in Pharmacies Across the U.S.

Cue's molecular COVID-19 self-test provides lab-quality results in 20 minutes SAN DIEGO, March 16, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), the healthcare technology company behind the most accurate at-home COVID-19 test* in the U.S., today announced that its molecular COVID-19 test is now available to individual consumers in Canada. The Cue Health Monitoring System (Reader) and Cue's molecular COVID-19 test for home, can be accessed through Cue's eCommerce site and in-app shop.

Cue Health's Pioneering Smart Home Lab and PCR-quality COVID-19 Test Now Available in Canada

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 29, 2022. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (888) 708-0136 for do

Cue Health to Announce Fourth Quarter and Full-Year 2021 Financial Results

SAN DIEGO , March 3, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it is further collaborating with the University of Pittsburgh Medical Center Children's Community Pediatrics ("UPMC CCP"), part of UPMC Children's Hospital of Pittsburgh, Pennsylvania. Cue will expand its distribution of Cue's Health Monitoring Systems and Cue COVID-19 tests to additional pediatric clinics to support testing for even more patients, physicians, nurses, and staff.

Cue Health Expands Collaboration with UPMC Children's Community Pediatrics to Bring Highly Accurate, Molecular Testing to an Expanded Network of Clinics

Cardinal Health

SAN DIEGO and DUBLIN, Ohio, Feb. 17, 2022 /PRNewswire/ -- Today Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, and Cardinal Health (NYSE: CAH) announced expanded distribution of Cue's professional use and over-the-counter COVID-19 tests. Cue selected Cardinal Health, which serves nearly 90% of US hospitals and over 60,000 pharmacies, as one of its primary distributors due to a demonstrated expertise in helping commercialize diagnostic technologies.

Cue Health Taps Cardinal Health to Distribute its Pioneering Molecular COVID-19 Tests

Cue Health (HLTH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Cue Health (HLTH) Might Surprise This Earnings Season

SAN DIEGO, Feb. 7, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it will provide Cue Health Monitoring Systems and Cue COVID-19 tests to Johns Hopkins Medicine (JHM), which includes Johns Hopkins University School of Medicine and The Johns Hopkins Hospital and Health System. The portable monitoring system and tests will be utilized by physicians, scientists, health professionals, faculty and staff as part of JHM's commitment to health and well-being among its entire employee population.

Cue Health to Provide Highly-Accurate, Molecular COVID-19 Tests to Johns Hopkins Medicine

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 12:30 p.m. Eastern Time. The webcast link is available only for those who are attending the BTIG conference. About Cue Health Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access h

Cue Health to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, (“Cue') today reported preliminary unaudited revenue for fourth quarter and full year 2021. Preliminary Fourth Quarter and Full Year Highlights Preliminary fourth quarter 2021 revenue of $188 million to $193 million, compared with $13 million in fourth quarter 2020 Preliminary fourth quarter 2021 revenue reflects increased customer diversification, with total private sector revenue outpacing total publi

Cue Health Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Biotech companies have been incredibly busy since March 2020 shifting entire operations to focus on COVID-19 issues, resulting in record levels of financing.

Cue Health: Significant Growth Potential Looking Beyond The Pandemic

SAN DIEGO, Jan. 6, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it will develop an Omicron-Genotyping COVID-19 test to be used in professional point-of-care settings as part of the company's ongoing work with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response. The Omicron-specific test will complement Cue's existing highly-accurate, molecular COVID-19 test, which can detect all known COVID-19 variants, including Omicron, a finding announced by the company in November.

Cue Health to Develop Omicron-Genotyping COVID-19 Test in Partnership with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA)

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq:HLTH), a healthcare technology company, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. Eastern Time. A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company's website at: www.cuehealth.com. About Cue Health Cue Health (Nasdaq:HLTH) is a healthcare technology company t

Cue Health to Present at the 40th Annual J.P. Morgan Healthcare Conference

Microbot Medical

Cassava Sciences Inc

Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.

Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist

It's a good time to be a company that sells a test-at-home COVID diagnostics kit.

Why Cue Health Blasted Higher Today

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced its first airline partnership with Air Canada to provide U.S.-based passengers with access to Cue's molecular COVID-19 test: the most accurate* self-test on the market.  Air Canada's U.S.-based customers can now meet Canada's specific travel testing requirements using Cue's  COVID-19 tests, which can be purchased three, six, or 10 at a time along with the reusable and portable Cue Cartridge Reader, which processes test results in about 20 minutes.

First-of-its-kind Cue Health Partnership with Air Canada Provides U.S.-based Customers with Special Access to the Most Accurate COVID-19 Self-Test

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a health technology company, today announced that it has appointed Nitin Duggal as its first Chief Marketing Officer, effective immediately. In his new role, he will be responsible for leading all marketing initiatives at Cue, including partners, direct to consumer, customers, employers, and providers.

Cue Health Appoints Nitin Duggal as Chief Marketing Officer

SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore.

Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing

SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular (NAAT) technology, can detect the Omicron variant.

Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant

SAN MATEO, Calif. and SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, announced a new collaboration today to provide individuals who test positive on Cue's at-home molecular COVID-19 test the opportunity to learn which variant they have contracted as part of a broader research study on the SARS-CoV-2 virus.

Helix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing Information

Cue Health Inc. (HLTH) CEO Ayub Khattak Q3 2021 Results - Earnings Call Transcript

Cue Health Inc (NASDAQ: HLTH) reported Q3 sales of $223.7 million, compared to +63% sequentially. Public Sector revenue was $129.5 million, compared to $105.0 in Q2 FY21, driven by additional deliveries to DOD / HHS under the existing agreement.

Cue Health Reports Q3 Profit On Higher Sales, Annual Guidance Above Consensus

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a mission-driven healthcare technology company, today reported financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Reported record total revenue of $223.7 million for the third quarter of 2021, a 63% increase compared to the second quarter of 2021 Public sector revenue of $129.5 million, up 23% for the third quarter of 2021 compared to the second quarter of 2021 Private sector revenue o

News for Cue Health Stock (HLTH)